Уникальная гибридная РНК, обнаруженная только у женщин, может регулировать иммунную систему

A Hybrid RNA Found Only in Women Was Long Blamed on Cancer, and It May Help Run the Immune System For decades, RNA molecules stitched together from two different genes were treated as evidence that something had gone wrong. Cancer is a disease of copying errors, and these hybrid transcripts looked like copying errors, so the field largely filed them under tumor biology. Researchers at the University of Virginia School of Medicine have described one that appears in healthy women, arises from the X chromosome that is supposed to be switched off, and tracks with how severely women get sick. Their findings were published in May in Science Advances. The Molecule That Only Shows Up in Women The transcript is called UBA1-CDK16. It fuses sequences from two neighboring X-linked genes, UBA1 and CDK16, through a process called cis-splicing, in which transcription machinery runs past the end of one gene and continues into the next. Both parent genes are expressed in men and women alike. The fused product is not. The team, led by Hui Li of UVA's Department of Pathology and the UVA Comprehensive Cancer Center, screened RNA-sequencing data from 425 whole-blood samples in a public genomics database to identify the transcript, then validated it in more than 1,200 additional blood samples from a hospital population. They found that the fusion is enabled by a chromatin loop at the junction site that occurs only in female cells, physically bringing the two regions together. Evolutionary analysis indicated the transcript became female-specific in humans through at least two independent routes. Women carry two X chromosomes, one of which is largely inactivated in each cell. According to UVA, Li found that the inactive X produces this particular molecule, which he could then detect in women's blood. Chimeric RNAs were once believed to be cancer-specific, Li said in a statement from UVA Health, but this work shows they "can also be part of normal physiology." The COVID Signal The most attention-grabbing observation involves infection severity. Li reported that the chimeric RNA was absent in 50 percent of women who developed severe COVID-19, while it was present in women who remained asymptomatic. Declining transcript levels correlated with worsening infection. He suspects the connection runs through neutrophils, the white blood cells that arrive first at sites of infection. The functional work indicated that UBA1-CDK16 is enriched in the myeloid lineage, which gives rise to neutrophils, and may help regulate myeloid cell development. Female COVID-19 patients who tested negative for the transcript had altered neutrophil counts, and neutrophil counts have already been studied as a predictor of COVID-19 outcomes, which makes the link plausible rather than proven. This is correlation. Losing the transcript may contribute to severe illness, or severe illness may alter its expression, or both may follow from something else entirely. The study does not settle the direction. An Argument About the Genome Itself The paper's broader claim is not really about COVID. It is about how much unconventional molecular activity the human genome contains that standard analysis has been discarding as noise. Humans carry roughly the same number of genes as fruit flies and worms, a fact that has bothered biologists since the human genome was sequenced. Alternative splicing, RNA editing, and alternative polyadenylation are all understood to expand the output of a fixed gene count. Li's group argues that chimeric RNAs belong on that list and that they represent another way to expand the functional genome without adding genes. The idea has been building for years. Earlier work established that chimeric transcripts arise in normal, non-cancerous cells through ordinary RNA processing rather than chromosomal rearrangement. What UBA1-CDK16 adds is a sex-specific example with an identified biogenesis mechanism and a candidate function. An earlier preprint version of the work laid out the same core findings. The Autoimmune Angle and Its Limits Li also suggests the transcript may act as a natural brake protecting women from excessive autoimmune activity. Women develop autoimmune disorders far more often than men, and the X chromosome carries an unusually large share of immune genes, so a female-specific X-derived regulator is an appealing candidate. He is urging further research rather than claiming an answer. Several cautions accompany this. The functional findings are described as suggestive by the authors themselves, using hedged wording about what the transcript may regulate. Much of the work is computational and cell-based. The autoimmune connection is a hypothesis generated by the data, not something the study tested. And a blood test built on this molecule, floated as a possible application for identifying women at higher risk of poor outcomes, does not exist and has not been validated in any clinical population. The research was supported by the National Institute of General Medical Sciences under grant R01GM132128. UVA states that the scientists have no financial interest in the work, a disclosure worth noting given that the researchers explicitly raise biomarkers and therapeutic targets as future directions. Key Questions Answered What is a chimeric RNA? An RNA transcript containing sequences from two different genes. They were long assumed to be products of chromosomal rearrangement in cancer, but many arise from ordinary splicing in healthy cells. Why is UBA1-CDK16 found only in women? It forms when transcription runs from UBA1 into the neighboring CDK16 gene, a process enabled by a chromatin loop that occurs only in female cells. UVA researchers report the inactive X chromosome produces it. What is the COVID-19 connection? The transcript was absent in 50 percent of women with severe COVID-19 and present in asymptomatic women, with lower levels tracking greater severity. This is an association, not a demonstrated cause. Could this become a blood test? The researchers raise it as a possibility because the molecule is detectable in blood. No such test exists, and none has been validated in patients. How large was the study? The transcript was identified using RNA sequencing from 425 blood samples and validated in more than 1,200 additional blood samples, alongside laboratory functional work. What does this say about autoimmune disease? Li hypothesizes the molecule may restrain excessive autoimmune activity in women, but the study did not test that. He has called for additional research. Published by Medicaldaily.com